Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Finished Goods (2017 - 2024)

China Pharma Holdings' Finished Goods history spans 8 years, with the latest figure at $1.3 million for Q3 2024.

  • For Q3 2024, Finished Goods rose 6.83% year-over-year to $1.3 million; the TTM value through Sep 2024 reached $1.3 million, up 6.83%, while the annual FY2023 figure was $1.5 million, 166.73% up from the prior year.
  • Finished Goods reached $1.3 million in Q3 2024 per CPHI's latest filing, down from $1.5 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $1.7 million in Q1 2024 to a low of $551000.0 in Q4 2021.
  • Average Finished Goods over 5 years is $1.2 million, with a median of $1.3 million recorded in 2022.
  • Peak YoY movement for Finished Goods: tumbled 46.0% in 2021, then skyrocketed 166.73% in 2023.
  • A 5-year view of Finished Goods shows it stood at $960375.0 in 2020, then crashed by 42.63% to $551000.0 in 2021, then changed by 0.0% to $551000.0 in 2022, then soared by 166.73% to $1.5 million in 2023, then decreased by 11.91% to $1.3 million in 2024.
  • Per Business Quant, the three most recent readings for CPHI's Finished Goods are $1.3 million (Q3 2024), $1.5 million (Q2 2024), and $1.7 million (Q1 2024).